Aerie completes enrollment in phase 2 trial of AR-1105

Enrollment is complete in a phase 2 clinical trial of AR-1105 for the treatment of macular edema associated with retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.

The trial, which is taking place at 19 U.S. centers, is evaluating the safety, tolerability and efficacy of AR-1105 (dexamethasone intravitreal implant).

“We are grateful to our investigators and the patients who have enrolled in this proof-of-concept study for our proprietary sustained-release technology,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We plan to conduct an interim analysis when the first 20 patients have reached the 6-month time point, which should be before the end of this year, making preliminary data available in 2020.”

The trial’s enrollment target of 45 patients was reached ahead of schedule, and a few additional patients are being screened to possibly bring the number of study subjects to 49, the release said.

Enrollment is complete in a phase 2 clinical trial of AR-1105 for the treatment of macular edema associated with retinal vein occlusion, Aerie Pharmaceuticals announced in a press release.

The trial, which is taking place at 19 U.S. centers, is evaluating the safety, tolerability and efficacy of AR-1105 (dexamethasone intravitreal implant).

“We are grateful to our investigators and the patients who have enrolled in this proof-of-concept study for our proprietary sustained-release technology,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release. “We plan to conduct an interim analysis when the first 20 patients have reached the 6-month time point, which should be before the end of this year, making preliminary data available in 2020.”

The trial’s enrollment target of 45 patients was reached ahead of schedule, and a few additional patients are being screened to possibly bring the number of study subjects to 49, the release said.